New offerings broaden the company’s fast-growing product portfolio

LEHI, Utah, Jan. 5, 2026 — CivicaScript®, LLC, a nonprofit focused on making low-cost generic medications and biosimilars accessible to U.S. patients, today announced that two new products are now available: insulin glargine-yfgn and ustekinumab-aauz.

Civica insulin glargine-yfgn is used to help improve glycemic control in adult and child patients with diabetes mellitus and is interchangeable¹ with Lantus®² (insulin glargine). It stems from joint work by Civica, CivicaScript, the Civica Foundation and other partners to boost access to affordable insulin.

CivicaScript markets Civica insulin glargine-yfgn nationwide. Through a partnership with California’s CalRx® program, it will bear the CalRx brand in California pharmacies.

Ustekinumab-aauz treats chronic inflammatory conditions in specific patients with plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. It is interchangeable³ with the reference product Stelara®⁴ (ustekinumab).

“We’re proud to start the New Year by increasing access to two vital biosimilars that can reduce costs for patients and health plans,” said CivicaScript President Brent J. Eberle. “Our expanding portfolio proves that putting patients first isn’t just ethical – it’s a tested way to deliver affordable generics and biosimilars.”

Civica insulin glargine-yfgn comes in prefilled pens at the lowest listed price in today’s long-acting insulin market. CivicaScript supplies it to U.S. pharmacies for $45 per box of five pens – a major discount from typical current prices. The company’s maximum suggested consumer price (MaxRPTM policy) is $55 or less. Out-of-pocket costs may be even lower, depending on insurance coverage.

This consistent, clear pricing differs from other manufacturers’ copay assistance programs, which require patients to enroll in plans that can change without warning.

CivicaScript offers ustekinumab-aauz in pre-filled syringes for subcutaneous injection in two strengths. The Wholesale Acquisition Cost (WAC) for a 12-week supply of 90 mg is $985, and $575 for 45 mg. This affordable, straightforward price is available to CivicaScript’s members and partners, including health plans and pharmacy benefit managers.

₁ . 
₂ Lantus® is a registered trademark of sanofi-aventis U.S. LLC. 
₃ . 
₄ Stelara® is a registered trademark of Johnson & Johnson.  

About CivicaScript

CivicaScript is introducing unmatched transparency to the drug supply chain to make high-quality generic medications affordable and accessible for all. As a nonprofit, it’s dedicated to offering affordable, essential generics and biosimilars to support community health and well-being. For more details on the organization and its mission, visit our . CivicaScript is Civica, Inc.’s outpatient medication division.

About insulin glargine-yfgn

Do not water down or combine insulin glargine-yfgn with any other insulin or solution. Mixing or diluting it can make the solution cloudy and change how quickly it works or its peak effectiveness in unpredictable ways. Do not use an insulin pump or intravenous injection to give insulin glargine-yfgn, as this can cause hypoglycemia. For full prescribing and patient information – including warnings, precautions, potential side effects and drug interactions – please see .

About ustekinumab-aauz

Indications: Ustekinumab-aauz is an IL-12/23 antagonist used to treat adult patients with moderate to severe plaque psoriasis who are eligible for phototherapy or systemic therapy; active psoriatic arthritis; moderately to severely active Crohn’s disease; and moderately to severely active ulcerative colitis. It’s also approved for children ages 6 and older with moderate to severe plaque psoriasis eligible for phototherapy or systemic therapy, and for kids 6 and older with active psoriatic arthritis.

Contraindications: Ustekinumab-aauz should not be used by patients with severe allergic reactions to ustekinumab products or any of its excipients. For more information, please see .

You’re urged to report adverse side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Media Contact 
Liz Power, Vice President, Communications
 
860 501 3849

SOURCE CivicaScript